9OF.F Stock Analysis
9O
Uncovered
BioRestorative Therapies Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. The company is headquartered in Melville, New York and currently employs 7 full-time employees. The company went IPO on 2001-07-11. The company offers two developmental programs, namely Disc/Spine Program (brtxDisc) and Metabolic Program (ThermoStem), which relate to the treatment of disc/spinedisease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous hypoxic cultured mesenchymal stem cell (MSC) product derived from a patient's own bone marrow and formulated with a biomaterial carrier (platelet lysate). BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The company is engaged in developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC), to generate brown adipose tissue (BAT).